Sugi Predict

Sugi Predict / Targets / KDM3B

KDM3B

Lysine-specific demethylase 3B · Q7LBC6 · KDM3B on Sugi Atlas →

1,252 patent compounds predicted against KDM3B, 581 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15349327 SCHEMBL15349327 0.53 11/20
SCHEMBL2219244 SCHEMBL2219244 0.50 11/20
SCHEMBL23900635 SCHEMBL23900635 0.50 11/20
SCHEMBL4765181 SCHEMBL4765181 0.47 11/20
SCHEMBL10561964 SCHEMBL10561964 0.74 10/20
SCHEMBL4766387 SCHEMBL4766387 0.61 10/20
SCHEMBL13295349 SCHEMBL13295349 0.50 10/20
SCHEMBL23900414 SCHEMBL23900414 0.50 10/20
SCHEMBL9956612 SCHEMBL9956612 0.47 10/20
SCHEMBL29351316 SCHEMBL29351316 0.46 10/20
SCHEMBL5867339 SCHEMBL5867339 0.45 10/20
SCHEMBL22868063 SCHEMBL22868063 0.49 9/20
SCHEMBL11293505 SCHEMBL11293505 0.50 8/20
SCHEMBL6297322 SCHEMBL6297322 0.38 7/20
SCHEMBL19860916 SCHEMBL19860916 0.35 7/20
SCHEMBL9781009 SCHEMBL9781009 0.53 6/20
SCHEMBL26063161 SCHEMBL26063161 0.56 5/20
SCHEMBL26288583 SCHEMBL26288583 0.49 5/20
SCHEMBL19643736 SCHEMBL19643736 0.47 5/20
SCHEMBL19661703 SCHEMBL19661703 0.47 5/20

Clinical trials — most relevant to KDM3B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia PHASE1RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
The Danish TURNER Cryopreservation Study nanRECRUITING
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
MIF Involvement in AML nanACTIVE_NOT_RECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy nanUNKNOWN
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia nanRECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KDM3B binder may also engage these)

ProteinNameSimilarity
Q6ZPY7 — 1.000 Q6ZPY7 →
Q8BZ32 — 1.000 Q8BZ32 →
Q8C3W1 — 0.998 Q8C3W1 →
Q71F56 — 0.997 Q71F56 →
P10244 — 0.997 P10244 →
Q8R5I7 — 0.997 Q8R5I7 →
E9Q555 — 0.997 E9Q555 →
Q9Y6A5 — 0.997 Q9Y6A5 →
Q3T0A6 — 0.996 Q3T0A6 →
Q9JL04 — 0.996 Q9JL04 →
Q5DW34 — 0.996 Q5DW34 →
Q7TPM1 — 0.996 Q7TPM1 →
Q9CWL2 — 0.995 Q9CWL2 →
Q9ET54 — 0.995 Q9ET54 →
A4IFJ0 — 0.995 A4IFJ0 →
Q5VZ18 — 0.995 Q5VZ18 →
Q9UHV7 — 0.995 Q9UHV7 →
Q5ZK74 — 0.995 Q5ZK74 →
Q61329 — 0.995 Q61329 →
Q9NYI0 — 0.995 Q9NYI0 →
O08696 — 0.995 O08696 →
Q86V15 — 0.995 Q86V15 →
Q76LL6 — 0.995 Q76LL6 →
Q60988 — 0.995 Q60988 →
P59808 — 0.995 P59808 →
Q80WT2 — 0.994 Q80WT2 →
Q8BSD5 — 0.994 Q8BSD5 →
Q8BJS7 — 0.994 Q8BJS7 →
D3Z8E6 — 0.994 D3Z8E6 →
D6RIA3 — 0.994 D6RIA3 →